Multiple-sclerosis

New approach to Multiple Sclerosis treatment using immunosuppression and stem cells shows promise

New clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS). Five years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression …

New approach to Multiple Sclerosis treatment using immunosuppression and stem cells shows promise Read More »

Multiple Sclerosis medication alemtuzumab can trigger severe B cell mediated brain inflammation

The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects. This was the finding by a team led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold from the Department of Neurology of the Ruhr-Universität Bochum at St. Josef’s Hospital. In the journal Lancet Neurology, the scientists report on two patients for …

Multiple Sclerosis medication alemtuzumab can trigger severe B cell mediated brain inflammation Read More »

Multiple sclerosis pathogenesis: association between amount of leaked hemoglobin and severity of brain shrinkage

A leak of a protein called hemoglobin from damaged red blood cells may be associated with brain shrinkage in multiple sclerosis. This is the conclusion of a team from Imperial College London, whose early-stage findings suggest treatments that lower levels of hemoglobin could slow progression of the disease. Haemoglobin carries iron and oxygen around the …

Multiple sclerosis pathogenesis: association between amount of leaked hemoglobin and severity of brain shrinkage Read More »